It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Minichromosome maintenance protein 10 (MCM10) is essential for eukaryotic DNA replication. Here, we describe compound heterozygous MCM10 variants in patients with distinctive, but overlapping, clinical phenotypes: natural killer (NK) cell deficiency (NKD) and restrictive cardiomyopathy (RCM) with hypoplasia of the spleen and thymus. To understand the mechanism of MCM10-associated disease, we modeled these variants in human cell lines. MCM10 deficiency causes chronic replication stress that reduces cell viability due to increased genomic instability and telomere erosion. Our data suggest that loss of MCM10 function constrains telomerase activity by accumulating abnormal replication fork structures enriched with single-stranded DNA. Terminally-arrested replication forks in MCM10-deficient cells require endonucleolytic processing by MUS81, as MCM10:MUS81 double mutants display decreased viability and accelerated telomere shortening. We propose that these bi-allelic variants in MCM10 predispose specific cardiac and immune cell lineages to prematurely arrest during differentiation, causing the clinical phenotypes observed in both NKD and RCM patients.
Minichromosome maintenance protein 10 (MCM10) is critical for eukaryotic DNA replication. Here, by modelling MCM10 variants in human cell lines, the authors reveal a mechanism of MCM10-associated disease, finding that loss of MCM10 function constrains telomerase activity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details













1 University of Minnesota, Department of Biochemistry, Molecular Biology, and Biophysics, Minneapolis, USA (GRID:grid.17635.36) (ISNI:0000000419368657)
2 University of North Carolina, Department of Biochemistry and Biophysics, Chapel Hill, USA (GRID:grid.410711.2) (ISNI:0000 0001 1034 1720)
3 Oxford Medical Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (GRID:grid.410556.3) (ISNI:0000 0001 0440 1440)
4 University of Oxford, Wellcome Centre Human Genetics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Oxford NIHR Biomedical Research Centre, Oxford, UK (GRID:grid.454382.c)
5 University of Oxford, Department of Haematology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
6 Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (GRID:grid.410556.3) (ISNI:0000 0001 0440 1440)
7 University of Oxford, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
8 Columbia University, Vagelos College of Physicians and Surgeons, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
9 University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486)